These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 25982916)

  • 1. Changes in the pharmacokinetics of teicoplanin in patients with hyperglycaemic hypoalbuminaemia: Impact of albumin glycosylation on the binding of teicoplanin to albumin.
    Enokiya T; Muraki Y; Iwamoto T; Okuda M
    Int J Antimicrob Agents; 2015 Aug; 46(2):164-8. PubMed ID: 25982916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Albumin concentration significantly impacts on free teicoplanin plasma concentrations in non-critically ill patients with chronic bone sepsis.
    Brink AJ; Richards GA; Lautenbach EE; Rapeport N; Schillack V; van Niekerk L; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2015 Jun; 45(6):647-51. PubMed ID: 25819167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Specific variability of teicoplanin protein binding in patients receiving continuous hemodiafiltration-comparison with hypoalbuminemia patients].
    Yanagimoto H; Teramatsu T; Goto J; Yanagisawa M; Harii N; Suzuki M; Hanawa T; Matsuda K; Oguchi T
    Yakugaku Zasshi; 2013; 133(6):711-7. PubMed ID: 23558910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of Teicoplanin on the PT-INR Controlled by Warfarin in Infection Patients].
    Nakano T; Nakamura T; Nakamura Y; Irie K; Sato K; Matsuo K; Imakyure O; Ogata K; Mishima K; Kamimura H
    Yakugaku Zasshi; 2017; 137(7):909-916. PubMed ID: 28674307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a teicoplanin loading regimen that rapidly achieves target serum concentrations in critically ill patients with severe infections.
    Nakamura A; Takasu O; Sakai Y; Sakamoto T; Yamashita N; Mori S; Morita T; Nabeta M; Hirayu N; Yoshiyama N; Moroki M; Tashiro K; Kannae M
    J Infect Chemother; 2015 Jun; 21(6):449-55. PubMed ID: 25726436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change of teicoplanin loading dose requirement for incremental increases of systemic inflammatory response syndrome score in the setting of sepsis.
    Nakano T; Nakamura Y; Takata T; Irie K; Sano K; Imakyure O; Mishima K; Futagami K
    Int J Clin Pharm; 2016 Aug; 38(4):908-14. PubMed ID: 27125378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of teicoplanin concentrations and safety analysis in neonates.
    Yamada T; Kubota T; Nakamura M; Ochiai M; Yonezawa M; Yano T; Kawashiri T; Egashira N; Hara T; Masuda S
    Int J Antimicrob Agents; 2014 Nov; 44(5):458-62. PubMed ID: 25218156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy.
    Byrne CJ; Parton T; McWhinney B; Fennell JP; O'Byrne P; Deasy E; Egan S; Enright H; Desmond R; Ryder SA; D'Arcy DM; McHugh J; Roberts JA
    J Antimicrob Chemother; 2018 Apr; 73(4):995-1003. PubMed ID: 29272419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors.
    Barbot A; Venisse N; Rayeh F; Bouquet S; Debaene B; Mimoz O
    Intensive Care Med; 2003 Sep; 29(9):1528-34. PubMed ID: 12856119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI Study.
    Roberts JA; Stove V; De Waele JJ; Sipinkoski B; McWhinney B; Ungerer JP; Akova M; Bassetti M; Dimopoulos G; Kaukonen KM; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Starr T; Wallis SC; Lipman J;
    Int J Antimicrob Agents; 2014 May; 43(5):423-30. PubMed ID: 24630304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro protein binding of teicoplanin to neonatal serum.
    Sando M; Sato Y; Iwata S; Akita H; Sunakawa K
    J Infect Chemother; 2004 Oct; 10(5):280-3. PubMed ID: 16163462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A simplified chart for determining the initial loading dose of teicoplanin in critically ill patients.
    Yoshida S; Suzuki A; Ohmori T; Niwa T; Okada H; Suzuki K; Kobayashi R; Doi T; Kitaichi K; Matsuura K; Murakami N; Ogura S; Itoh Y
    Pharmazie; 2017 Jan; 72(1):53-57. PubMed ID: 29441898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of breakthrough Gram-positive cocci infection during vancomycin vs teicoplanin therapy in patients receiving haematopoietic stem cell transplantation.
    Ohata K; Kitagawa J; Niwa T; Takahashi-Yamauchi T; Harada S; Matsumoto T; Nakamura N; Nakamura H; Kanemura N; Shimizu M; Suzuki A
    J Clin Pharm Ther; 2020 Dec; 45(6):1342-1348. PubMed ID: 32656902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients.
    Ulldemolins M; Roberts JA; Rello J; Paterson DL; Lipman J
    Clin Pharmacokinet; 2011 Feb; 50(2):99-110. PubMed ID: 21142293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of teicoplanin dosing designs to achieve a new target trough concentration.
    Ueda T; Takesue Y; Nakajima K; Ichki K; Wada Y; Tsuchida T; Takahashi Y; Ishihara M; Tatsumi S; Kimura T; Ikeuchi H; Uchino M
    J Infect Chemother; 2012 Jun; 18(3):296-302. PubMed ID: 22065089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of Therapeutic Drug Monitoring of Teicoplanin at the Onset of Febrile Neutropenia.
    Takigawa M; Tanaka H; Suwa J; Obara T; Maeda Y; Sato M; Shimazaki Y; Onoda T; Ishigami A; Ishii T
    Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109716
    [No Abstract]   [Full Text] [Related]  

  • 17. Improvement of Predictivity of Teicoplanin Serum Trough Concentrations at Steady State Calculated by Vancomycin Pharmacokinetic Parameter.
    Kobayashi R; Otomo S; Shiba Y; Ebinuma K; Sudoh T
    Yakugaku Zasshi; 2016; 136(11):1557-1562. PubMed ID: 27803487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of individual adjustment of initial loading dosage of teicoplanin based on population pharmacokinetics.
    Niwa T; Imanishi Y; Ohmori T; Matsuura K; Murakami N; Itoh Y
    Int J Antimicrob Agents; 2010 May; 35(5):507-10. PubMed ID: 20185275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical localization and pharmacokinetics of the anti-MRSA drug teicoplanin in rat kidney using a newly developed specific antibody.
    Yamamoto Y; Yamamoto Y; Saita T; Shin M
    Med Mol Morphol; 2021 Sep; 54(3):227-236. PubMed ID: 33864519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of the predicted free blood concentration of teicoplanin with the development of renal dysfunction.
    Sugiyama K; Hirai K; Suyama Y; Furuya K; Ito K
    Eur J Clin Pharmacol; 2024 Apr; 80(4):597-602. PubMed ID: 38285202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.